Fig. 1

Disposition of Patients Through 5 Years in SELECT-EARLY. AE, adverse event; CDAI, Clinical Disease Activity Index; D/C, discontinued; L/C, logistical constraints; LoE, lack of efficacy; MTX, methotrexate; QD, once daily; UPA, upadacitinib; W, week. ^aPatients in the UPA 30 mg treatment group were later switched to the approved UPA 15 mg dose per protocol amendment. The switch occurred at different visits across the patient population, with the earliest switch occurring at the week 108 visit. ^bAt week 26, patients who did not achieve CDAI remission and at least 20% improvement from baseline in tender and swollen joint counts received rescue therapy (addition of MTX to insufficient responders in the UPA groups and addition of UPA 15/30 mg to insufficient responders in the MTX group)